Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: A novel finding

Emily S. Yin, BS, Mariam B. Totonchy, MD, and Jonathan S. Leventhal, MD

New Haven, Connecticut

Key words: adverse events; immunomodulators; immunotherapy; nivolumab; programmed cell death 1; vitiligo.

INTRODUCTION

Programmed cell death 1 receptor (PD-1) inhibitors enhance the antitumoral immune response via immune checkpoint inhibition. In a healthy immune system, the binding of ligands to PD-1 induces T-cell inactivation and prevents overactive immune responses. However, PD-1 ligands are also expressed by a variety of tumors, including melanomas, renal cell carcinomas, and brain tumors, in an effort to evade the host immune response. Although immune checkpoint inhibitors have revolutionized care for cancer patients, new cutaneous and systemic toxicities are still being discovered.

Nivolumab is a humanized IgG4 anti-PD-1 monoclonal antibody that is currently approved by the US Food and Drug Administration for the treatment of melanoma, non–small cell lung cancer, renal cancer, and classical Hodgkin lymphoma. Several adverse effects of immune-targeting therapies are described and are referred to as immune-related adverse events (irAEs). Systemic irAEs include enterocolitis, pneumonitis, hepatitis, nephritis, hypophysitis, and autoimmune thyroid disease. In addition, dermatologic toxicity is the most common irAE of checkpoint inhibitors and ranges from pruritus and mild dermatoses to severe reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis. Vitiligo-like depigmentation is well described in melanoma patients receiving immunotherapy with PD-1 inhibitors and may be associated with favorable outcomes.

CASE REPORT

A 66-year-old man with AML in remission after chemotherapy and non–small cell lung carcinoma previously treated with chemotherapy and local radiation was referred to the dermatology department with an asymptomatic, hypopigmented eruption that began 4 months after starting nivolumab. The patient was started on nivolumab as part of a phase II clinical trial. To our knowledge, this is the first reported case of vitiligo-like depigmentation associated with PD-1 inhibitor treatment in a patient with a nonmelanoma malignancy. Previous reports of PD-1 inhibitor–associated vitiligo-like depigmentation have been exclusively described in patients being treated for melanoma.

From the Department of Dermatology, Yale School of Medicine.

Funding sources: None.

Conflicts of interest: None declared.

Correspondence to: Jonathan S. Leventhal, MD, Department of Dermatology, Yale School of Medicine, 15 York Street, LMP 5040, New Haven, CT 06510. E-mail: Jonathan.leventhal@yale.edu.

JAAD Case Reports 2017;3:90-2.

2352-5126 © 2016 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

http://dx.doi.org/10.1016/j.jdcr.2016.10.008
found dozens of depigmented, oval macules and patches (0.5–3 cm), most prominent on the bilateral forearms (Fig 1), upper arms, and back (Fig 2). Scattered depigmented macules were noted on the bilateral temples, neck, medial canthi, and upper chest. The lesions had no associated scale or erythema. Examination under Wood’s lamp confirmed depigmentation (Fig 3). Aside from solar purpura on the forearms, the remainder of the total body skin examination was unremarkable, without any atypical pigmented lesions or lymphadenopathy. The diagnosis of PD-1 inhibitor–associated vitiligo-like depigmentation was made.

Given the asymptomatic nature of the findings, the patient elected for close monitoring with routine skin surveillance and no additional treatment. The patient subsequently underwent a complete ophthalmic examination with no evidence of ocular melanoma, and a repeat bone marrow biopsy found no evidence of disease recurrence. The patient continued treatment with nivolumab without additional adverse effects, and the vitiligo-like depigmentation remained stable at a 2-month follow-up examination with his oncologist.

**DISCUSSION**

PD-1 inhibitors are associated with a variety of cutaneous irAEs, including pruritus, maculopapular eruptions, eczema, lichenoid dermatoses, psoriasiform eruptions, vitiligo, sarcoidosis, and severe reactions such as Stevens-Johnson syndrome/toxic epidermal necrolysis. A recent review found that more than 40% of patients with melanoma treated with PD-1 inhibitors had cutaneous irAEs. Of PD-1 inhibitor–associated cutaneous irAEs, vitiligo-like depigmentation is relatively common, reported in more than 25% of patients with advanced stage III or IV melanoma on nivolumab. It has been hypothesized that PD-1 inhibitors induce vitiligo-like depigmentation in melanoma patients via the anti-melanoma immune response, which may also target healthy melanocytes owing to overlapping antigen expression. To the best of our knowledge, this case is the first reported instance of PD-1 inhibitor–associated vitiligo-like depigmentation in a patient with a nonmelanoma tumor. Although PD-1 inhibitor–associated vitiligo-like depigmentation has been associated with a favorable response to treatment in patients with metastatic melanoma, its prognostic value for nonmelanoma tumors is unknown. Furthermore, the mechanism by which vitiligo-like depigmentation occurred in a patient without a known melanoma remains unclear. One possible explanation is that an autoimmune predisposition was uncovered by T-cell activation via immunotherapy. An alternative explanation is that the patient...
had an undiagnosed cutaneous or mucosal melanoma that regressed and was not detectable on examination or radiographic imaging.

As PD-1 immunotherapy gains increasing popularity in the treatment of nonmelanoma cancers, the identification of additional patients with vitiligo-like depigmentation may shed light on the mechanism and prognostic value of this cutaneous adverse event.

REFERENCES

1. National Cancer Institute. Bethesda, MD: National Institutes of Health. Nivolumab. Available from: http://www.cancer.gov/about-cancer/treatment/drugs/nivolumab. Published January 7, 2015. [Updated May 19, 2016. Cited August 25, 2016.]

2. Goldinger SM, Stieger P, Meier B, et al. Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy. Clin Cancer Res. 2016;22(16):4023-4029.

3. Nakamura Y, Tanaka R, Asami Y, et al. Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study. J Dermatol. 2016. http://dx.doi.org/10.1111/1346-8138.13520.

4. Ohtsuka M, Miura T, Mori T, Ishikawa M, Yamamoto T. Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma. JAMA Dermatol. 2015;151(7):797-799.

5. Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 2016;28(4):254-263.

6. Houghton AN, Eisinger M, Albino AP, Cairncross JG, Old LJ. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med. 1982;156(6):1755-1766.

7. Teulings HE, Limpens J, Jansen SN, et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015;33(7):773-781.

Fig 3. Examination under Wood’s lamp highlights the widespread areas of depigmentation.